Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Tonix Pharmaceuticals and Bilthoven Biologicals Collaborate to Develop TNX-801 Mpox Vaccine
Latest Hotspot
3 min read
Tonix Pharmaceuticals and Bilthoven Biologicals Collaborate to Develop TNX-801 Mpox Vaccine
29 August 2024
Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.
Read →
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(3)
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(3)
29 August 2024
Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.
Read →
EU Approval Granted for Ordspono™ (odronextamab) to Treat Two Types of Lymphoma
Latest Hotspot
4 min read
EU Approval Granted for Ordspono™ (odronextamab) to Treat Two Types of Lymphoma
29 August 2024
Ordspono™ (odronextamab) has received approval in the EU for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.
Read →
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(2)
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(2)
29 August 2024
Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.
Read →
Vericel Announces FDA Approval and Market Release of MACI Arthro
Latest Hotspot
3 min read
Vericel Announces FDA Approval and Market Release of MACI Arthro
29 August 2024
This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.
Read →
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(1)
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(1)
29 August 2024
Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Read →
Roche's PiaSky receives EU approval as the first monthly subcutaneous therapy for PNH patients
Latest Hotspot
4 min read
Roche's PiaSky receives EU approval as the first monthly subcutaneous therapy for PNH patients
29 August 2024
Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 29
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 29
29 August 2024
Aug 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Phase 1 study outcomes of exidavnemab published in The Journal of Clinical Pharmacology
Latest Hotspot
2 min read
Phase 1 study outcomes of exidavnemab published in The Journal of Clinical Pharmacology
29 August 2024
BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.
Read →
How to quickly read pharmaceutical company financial reports?
DrugDeal Decode
6 min read
How to quickly read pharmaceutical company financial reports?
28 August 2024
This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 28
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 28
28 August 2024
Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
SIFI Gains European Commission Nod for AKANTIOR®
Latest Hotspot
4 min read
SIFI Gains European Commission Nod for AKANTIOR®
27 August 2024
SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.
Read →